Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Therapeutics seeking partner for ranolazine SR Phase III angina trials.

Executive Summary

CV THERAPEUTICS SEEKING PARTNER TO SUPPORT RANOLAZINE SR PHASE III TRIALS for angina, the company said in its recent initial public offering prospectus. "The company's clinical development plan for ranolazine assumes that Phase I data and several Phase II angina trials with [immediate-release] ranolazine combined with Phase I data and safety and tolerability data from a pilot Phase II trial for intermittent claudication with ranolazine [sustained release] will be accepted by the FDA to initiate Phase III trials with ranolazine SR," the prospectus cautions.

You may also be interested in...

Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street

CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts